Brent Hatzis-Schoch

2021 - Black Diamond Therapeutics

In 2021, Brent Hatzis-Schoch earned a total compensation of $2M as Chief Operating Officer, General Counsel at Black Diamond Therapeutics, a 32% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$149,226
Option Awards$1,411,832
Salary$438,901
Other$22,350
Total$2,022,309

Hatzis-Schoch received $1.4M in option awards, accounting for 70% of the total pay in 2021.

Hatzis-Schoch also received $149.2K in non-equity incentive plan, $438.9K in salary and $22.4K in other compensation.

Rankings

In 2021, Brent Hatzis-Schoch's compensation ranked 6,014th out of 12,415 executives tracked by ExecPay. In other words, Hatzis-Schoch earned more than 51.6% of executives.

ClassificationRankingPercentile
All
6,014
out of 12,415
52nd
Division
Manufacturing
2,546
out of 5,505
54th
Major group
Chemicals And Allied Products
1,113
out of 2,375
53rd
Industry group
Drugs
991
out of 2,096
53rd
Industry
Biological Products, Except Diagnostic Substances
242
out of 449
46th
Source: SEC filing on April 28, 2022.

Hatzis-Schoch's colleagues

We found three more compensation records of executives who worked with Brent Hatzis-Schoch at Black Diamond Therapeutics in 2021.

2021

David Epstein

Black Diamond Therapeutics

Chief Executive Officer

2021

Thomas Leggett

Black Diamond Therapeutics

Chief Financial Officer

2021

Fang Ni

Black Diamond Therapeutics

Chief Financial Officer

News

In-depth

You may also like